In melanomas, which also harbour BRAFV600E mutations, it has been demonstrated that BRAFV600E activates the MAPK pathway and controls proliferation of melanoma cells through the regulation of cyclin D1 and of the cyclin-dependent kinase inhibitor p27Kip1 [4-7]. Here, CDKN3 is linked to melanoma.